IVERIC bio announced that the FDA has completed its filing review and accepted the company’s New Drug Application for avacincaptad pegol, or ACP, a novel investigational complement C5 inhibitor for the treatment of geographic atrophy secondary to Age-Related Macular Degeneration. The NDA has been granted Priority Review with a Prescription Drug User Fee Act goal date of August 19, 2023. The company also announced that, at this time, the FDA has not identified any potential review issues and the FDA is not currently planning to hold an Advisory Committee meeting for ACP.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ISEE:
- Wells Fargo downgrades Apellis to Equal Weight, lowers price target to $58
- Opus Genetics acquires rights to two gene therapy candidates from Iveric bio
- After-Hours Movers
- Iveric bio sells IC-100 and IC-200 rights to Opus Genetics
- Iveric bio completes NDA submission to FDA for avacincaptad pegol to treat GA
